Another study has found that most new cancer medicines are massively expensive and rather useless. Read it here: Harrison P. Another Analysis Questions Efficacy of New Cancer Drugs.
That’s better evidence of a stronger effect than is available for ISO accreditation. Other cancer studies cited in the article enable authors to say that most of the drugs are inappropriate, unethical and should be stopped.
Just like UKAS accreditation.
Salas-Vega S, Iliopoulos O, Mossialos E. Assessment of Overall Survival, Quality of Life, and Safety Benefits Associated With New Cancer Medicines. JAMA Oncol. Published online December 29, 2016. doi:10.1001/jamaoncol.2016.4166